Logo image of GOVX

GEOVAX LABS INC (GOVX) Stock Fundamental Analysis

NASDAQ:GOVX - Nasdaq - US3736786068 - Common Stock - Currency: USD

0.4801  +0 (+0.69%)

After market: 0.5 +0.02 (+4.14%)

Fundamental Rating

3

Taking everything into account, GOVX scores 3 out of 10 in our fundamental rating. GOVX was compared to 555 industry peers in the Biotechnology industry. While GOVX seems to be doing ok healthwise, there are quite some concerns on its profitability. GOVX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GOVX had negative earnings in the past year.
GOVX had a negative operating cash flow in the past year.
GOVX had negative earnings in each of the past 5 years.
In the past 5 years GOVX always reported negative operating cash flow.
GOVX Yearly Net Income VS EBIT VS OCF VS FCFGOVX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

GOVX has a worse Return On Assets (-226.15%) than 90.45% of its industry peers.
With a Return On Equity value of -310.20%, GOVX is not doing good in the industry: 72.43% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -226.15%
ROE -310.2%
ROIC N/A
ROA(3y)-210.29%
ROA(5y)-163.35%
ROE(3y)-332.78%
ROE(5y)-290.99%
ROIC(3y)N/A
ROIC(5y)N/A
GOVX Yearly ROA, ROE, ROICGOVX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GOVX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GOVX Yearly Profit, Operating, Gross MarginsGOVX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

More info and screens

6

2. Health

2.1 Basic Checks

GOVX does not have a ROIC to compare to the WACC, probably because it is not profitable.
GOVX has more shares outstanding than it did 1 year ago.
GOVX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for GOVX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GOVX Yearly Shares OutstandingGOVX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
GOVX Yearly Total Debt VS Total AssetsGOVX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

GOVX has an Altman-Z score of -22.07. This is a bad value and indicates that GOVX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -22.07, GOVX is not doing good in the industry: 86.67% of the companies in the same industry are doing better.
There is no outstanding debt for GOVX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -22.07
ROIC/WACCN/A
WACC9.63%
GOVX Yearly LT Debt VS Equity VS FCFGOVX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

GOVX has a Current Ratio of 3.62. This indicates that GOVX is financially healthy and has no problem in meeting its short term obligations.
GOVX has a Current ratio of 3.62. This is comparable to the rest of the industry: GOVX outperforms 41.80% of its industry peers.
A Quick Ratio of 3.62 indicates that GOVX has no problem at all paying its short term obligations.
GOVX's Quick ratio of 3.62 is in line compared to the rest of the industry. GOVX outperforms 43.60% of its industry peers.
Industry RankSector Rank
Current Ratio 3.62
Quick Ratio 3.62
GOVX Yearly Current Assets VS Current LiabilitesGOVX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 76.33% over the past year.
Measured over the past years, GOVX shows a very strong growth in Revenue. The Revenue has been growing by 27.45% on average per year.
EPS 1Y (TTM)76.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.85%
Revenue 1Y (TTM)N/A
Revenue growth 3Y117.28%
Revenue growth 5Y27.45%
Sales Q2Q%N/A

3.2 Future

GOVX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.74% yearly.
Based on estimates for the next years, GOVX will show a very strong growth in Revenue. The Revenue will grow by 278.07% on average per year.
EPS Next Y70.43%
EPS Next 2Y34.58%
EPS Next 3Y32.74%
EPS Next 5YN/A
Revenue Next Year-68.85%
Revenue Next 2Y-41.42%
Revenue Next 3Y278.07%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
GOVX Yearly Revenue VS EstimatesGOVX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2024 2025 2027 100M 200M 300M
GOVX Yearly EPS VS EstimatesGOVX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 0 -5 -10 -15 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

GOVX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GOVX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GOVX Price Earnings VS Forward Price EarningsGOVX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GOVX Per share dataGOVX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as GOVX's earnings are expected to grow with 32.74% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.58%
EPS Next 3Y32.74%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GOVX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GEOVAX LABS INC

NASDAQ:GOVX (7/3/2025, 7:32:12 PM)

After market: 0.5 +0.02 (+4.14%)

0.4801

+0 (+0.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01
Earnings (Next)08-04 2025-08-04
Inst Owners12.48%
Inst Owner Change304.93%
Ins Owners0.55%
Ins Owner Change15.88%
Market Cap7.29M
Analysts81.82
Price Target10.91 (2172.44%)
Short Float %3.56%
Short Ratio0.65
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-18.85%
Min Revenue beat(2)-64.4%
Max Revenue beat(2)26.69%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.57%
PT rev (3m)-26.71%
EPS NQ rev (1m)2.7%
EPS NQ rev (3m)21.74%
EPS NY rev (1m)10.04%
EPS NY rev (3m)-31.31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-88.04%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-87.56%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.3
P/FCF N/A
P/OCF N/A
P/B 0.92
P/tB 0.92
EV/EBITDA N/A
EPS(TTM)-5.67
EYN/A
EPS(NY)-1.07
Fwd EYN/A
FCF(TTM)-1.65
FCFYN/A
OCF(TTM)-1.64
OCFYN/A
SpS0.37
BVpS0.52
TBVpS0.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -226.15%
ROE -310.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-210.29%
ROA(5y)-163.35%
ROE(3y)-332.78%
ROE(5y)-290.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.52
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.62
Quick Ratio 3.62
Altman-Z -22.07
F-Score5
WACC9.63%
ROIC/WACCN/A
Cap/Depr(3y)108.76%
Cap/Depr(5y)249.22%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.85%
EPS Next Y70.43%
EPS Next 2Y34.58%
EPS Next 3Y32.74%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y117.28%
Revenue growth 5Y27.45%
Sales Q2Q%N/A
Revenue Next Year-68.85%
Revenue Next 2Y-41.42%
Revenue Next 3Y278.07%
Revenue Next 5YN/A
EBIT growth 1Y13.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-83000.3%
EBIT Next 3Y649.13%
EBIT Next 5YN/A
FCF growth 1Y-34.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-35.2%
OCF growth 3YN/A
OCF growth 5YN/A